Camlin Fine Sciences Limited has informed the Exchange about Investor Presentation
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Camlin Fine Sciences reported FY26 revenue of Rs 17,233 mn (up 6% YoY), but EBITDA margin nearly halved to 6.2% from 13.3% in FY25 due to multiple headwinds. The company cited prolonged geopolitical conflict affecting raw material availability and logistics costs, increased local competition pressuring Straights prices, and rising interest costs as key challenges. Q4FY26 was particularly weak with EBITDA margin dropping to just 5%. Positively, the Blends business grew 17% annually with newly acquired Vinpai contributing Rs 165 mn in Q4. Management expects Vanillin realizations to improve following US tariff withdrawal and aims for higher growth momentum in Blends. CFS Europe is under liquidation to curtail losses. April FY27 revenue started strong at Rs 1,050+ mn.
Sharp margin deterioration and weak profitability in FY26 reflect significant operational pressures from geopolitical factors and competition. While the Blends segment shows resilience and new acquisitions add diversification, the stock may face near-term weakness due to compressed margins and negative PAT from continuing operations.